猴痘治療藥的全球市場 - 產業規模，佔有率，趨勢，機會，預測:各治療，各終端用戶，各地區(2017年～2027年)

全球猴痘治療藥的市場規模，在2023年～2027年的預測期間內預計以大幅度的年複合成長率成長。

市場成長，可能起因於在歐美人們之間病毒感染疾病突然發生。

本報告提供全球猴痘治療藥市場相關調查分析，各市場區隔的預測，各地區的分析，競爭情形等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 COVID-19對全球猴痘治療藥市場的影響

第5章 客戶的迴響

• 常見猴痘症狀
• 猴痘的盛行率:性別
• 猴痘的盛行率:各年齡層
• 猴痘的盛行率:各地區

第6章 全球猴痘治療藥市場預測

• 市場規模與預測
  • 各金額
• 市場佔有率與預測
  • 各治療(天花疫苗，抗病毒藥物，牛痘免疫球蛋白(VIG))
  • 各終端用戶(醫院，專門診療所，門診手術中心，其他)
  • 各企業(2021年)
  • 各地區
• 產品市場地圖

第7章 北美的猴痘治療藥市場預測

• 市場規模與預測
• 市場佔有率與預測
• 北美:各國分析
  • 美國的猴痘治療藥市場預測
  • 加拿大的猴痘治療藥市場預測

第8章 歐洲的猴痘治療藥市場預測

• 市場規模與預測
• 市場佔有率與預測
• 歐洲:各國分析
  • 英國的猴痘治療藥市場預測
  • 德國的猴痘治療藥市場預測
  • 法國的猴痘治療藥市場預測
  • 比利時的猴痘治療藥市場預測
  • 荷蘭的猴痘治療藥市場預測
  • 瑞典的猴痘治療藥市場預測
  • 義大利的猴痘治療藥市場預測
  • 西班牙的猴痘治療藥市場預測

第9章 亞太地區的猴痘治療藥市場預測

• 市場規模與預測
• 市場佔有率與預測
• 亞太地區:各國分析
  • 澳洲的猴痘治療藥市場預測
  • 新加坡的猴痘治療藥市場預測

第10章 中東、非洲的猴痘治療藥市場預測

• 市場規模與預測
• 市場佔有率與預測
• 中東、非洲:各國分析
  • 奈及利亞的猴痘治療藥市場預測

第11章 市場動態

• 促進因素
• 課題

第12章 市場趨勢與發展

第13章 競爭情形

• 企業簡介
  • Chimerix Inc.
  • SIGA Technologies, Inc.
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Hetero Drugs Limited
  • Mylan N.V.
  • Piramal Enterprises Limited
  • Olon S.p.A.
  • Teva Pharmaceutical Industries Limited
  • CIDIC Company Limited

第14章 策略性推薦事項

Global monkeypox therapeutics market is projected to register growth at a significant CAGR during the forecast period, 2023-2027. The market growth can be attributed to the sudden outburst of the viral infection among the population across Europe and United States. In the year 2003, monkeypox caused a commotion because it spread quickly, and the number of affected patients exceeded 40 in a matter of weeks. Although the disease spread was relatively well-controlled, the recent outbreak of infection and rapidly increasing cases pose a threat for another possible pandemic. Hence, the demand for effective treatment, vaccination, and other rare disease therapeutics are expected to support the growth of the global monkeypox therapeutics market over the next five years.

There is currently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and an increase in demand for pain and itch relief due to boils and rashes are positively influencing the growth of the global monkeypox therapeutics market.

Monkeypox is a viral infection that spreads like a highly communicable disease through mere touch and use of infected patient's material. The virus is related to smallpox, and the vaccination and drugs used to control smallpox are also somewhat effective against monkeypox diseases. Although no specific vaccine or treatment drug has yet been commercialised, research is still ongoing. Patients with compromised immunity, those suffering from chronic disease, certain skin conditions such as eczema, those recovering from a recent pandemic, and those suffering from other anti-viral infections are all at high risk of contracting the monkeypox.

Growing demand for timely vaccines and potential disease treatments may support the growth of the global monkeypox therapeutics market in the next five years. Governments are actively investing in the research and development of effective vaccines and drugs to control disease spread and treat affected patients. In addition, the government is taking steps to promote drug development using genetic engineering tools in order to provide vaccination in the event that the virus evolves and affects a larger portion of the population.

Genomic sequencing for the virus would elucidate the specific infection-causing sequences, which could aid in the early diagnosis of the viral infection and the development of effective vaccines for the population at risk of infection in the coming years. Furthermore, rising healthcare expenditures by the population is fuelling growing investments for the developmen to new vaccines, which is likely to aid the global monkeypox therapeutics market in the next five years.

The global monkeypox therapeutics market segmentation is based on treatment, end user, regional distribution, and competitive landscape. Based on treatment, the market is divided into smallpox vaccine, antivirals, and vaccinia immune globulin (VIG). The smallpox vaccine segment is anticipated to hold the largest share in the global monkeypox therapeutics market due to the rising number of cases of monkeypox.

Key players operating in the global monkeypox therapeutics market are Chimerix Inc., SIGA Technologies, Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Hetero Drugs Limited, Mylan N.V., Piramal Enterprises Limited, Olon S.p.A., Teva Pharmaceutical Industries Limited, CIDIC Company Limited, among others.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Objective of the Study:

• To analyze the historical growth in the market size of the global monkeypox therapeutics from 2017 to 2021.
• To estimate and forecast the market size of global monkeypox therapeutics market from 2023 to 2027 and growth rate until 2027.
• To classify and forecast the global monkeypox therapeutics market based on treatment, end user, region, and company.
• To identify the dominant region or segment in the global monkeypox therapeutics market.
• To identify drivers and challenges for the global monkeypox therapeutics market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global monkeypox therapeutics market.
• To identify and analyze the profiles of leading players operating in the global monkeypox therapeutics market.
• To identify key sustainable strategies adopted by market players in global monkeypox therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of the Global monkeypox therapeutics market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global monkeypox therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Monkeypox Therapeutics Market, By Treatment:

Smallpox Vaccine

Antivirals

Vaccinia Immune Globulin (VIG)

• Monkeypox Therapeutics Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

• Monkeypox Therapeutics Market, By Region:

North America

• United States
• Canada

Asia-Pacific

• Australia
• Singapore

Europe

• France
• Germany
• United Kingdom
• Belgium
• Netherlands
• Sweden
• Italy
• Spain

Middle East & Africa

• Nigeria

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global monkeypox therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Monkeypox Therapeutics Market

5. Voice of Customer

• 5.1. Commonly Observed Symptoms of Monkeypox
• 5.2. Monkeypox Prevalence, By Gender
• 5.3. Monkeypox Prevalence, By Age Group
• 5.4. Monkeypox Prevalence, By Region

6. Global Monkeypox Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
  • 6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 6.2.3. By Company (2021)
  • 6.2.4. By Region
• 6.3. Product Market Map

7. North America Monkeypox Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Monkeypox Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. Canada Monkeypox Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User

8. Europe Monkeypox Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. United Kingdom Monkeypox Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. Germany Monkeypox Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. France Monkeypox Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. Belgium Monkeypox Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Netherlands Monkeypox Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User
  • 8.3.6. Sweden Monkeypox Therapeutics Market Outlook
    • 8.3.6.1. Market Size & Forecast
      • 8.3.6.1.1. By Value
    • 8.3.6.2. Market Share & Forecast
      • 8.3.6.2.1. By Treatment
      • 8.3.6.2.2. By End User
  • 8.3.7. Italy Monkeypox Therapeutics Market Outlook
    • 8.3.7.1. Market Size & Forecast
      • 8.3.7.1.1. By Value
    • 8.3.7.2. Market Share & Forecast
      • 8.3.7.2.1. By Treatment
      • 8.3.7.2.2. By End User
  • 8.3.8. Spain Monkeypox Therapeutics Market Outlook
    • 8.3.8.1. Market Size & Forecast
      • 8.3.8.1.1. By Value
    • 8.3.8.2. Market Share & Forecast
      • 8.3.8.2.1. By Treatment
      • 8.3.8.2.2. By End User

9. Asia-Pacific Monkeypox Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. Australia Monkeypox Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. Singapore Monkeypox Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User

10. Middle East and Africa Monkeypox Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. Nigeria Monkeypox Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

• 13.1. Company Profiles
  • 13.1.1. Company Details
  • 13.1.2. Financials (As reported)
  • 13.1.3. Key Market Focus and Geographical Presence
  • 13.1.4. Pricing of Target Products
  • 13.1.5. Market positioning
• 13.2. Chimerix Inc.
• 13.3. SIGA Technologies, Inc.
• 13.4. Emergent BioSolutions Inc.
• 13.5. Bavarian Nordic A/S
• 13.6. Hetero Drugs Limited
• 13.7. Mylan N.V.
• 13.8. Piramal Enterprises Limited
• 13.9. Olon S.p.A.
• 13.10. Teva Pharmaceutical Industries Limited
• 13.11. CIDIC Company Limited

14. Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)